Book a Meeting

Anti-BCMA Antibody, ADCC Enchanced (BioBet-CB-056LX) (CAT#: BioBet-CB-056LX) Datasheet

Target
BCMA
Isotype
IgG1
Description
Anti-BCMA Antibody, ADCC Enchanced (BioBet-CB-056LX) is a glycosylation-modified anti-BCMA therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced BCMA antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
BCMA
Full Name
B-cell maturation antigen
Background
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. [provided by RefSeq, Jul 2008]
Alternative Names
B-cell maturation antigen; TNFRSF17; TNF receptor superfamily member 17; BCM; BCMA; CD269; TNFRSF13A
Gene ID
607
UniProt ID
Q02223
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-CB-056LX
Host
Humanized
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human BCMA (Belantamab) Antibody is derived from clone Belantamab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the BCMA, and it is intended for the research of Multiple myeloma.
Antibody Indication
Multiple myeloma

Multiple myeloma

Related Products

Anti-BCMA Antibody, Non-Fucosylated (BioBet-1832ZP) (CAT#: BioBet-1832ZP)
Anti-BCMA Antibody, Half-Life Extended (AES-0622-ZP1021) (CAT#: AES-0622-ZP1021)
Anti-BCMA Antibody, Recycling (AES-0622-ZP37) (CAT#: AES-0622-ZP37)
Anti-BCMA Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP365) (CAT#: AES-0622-ZP365)
Anti-BCMA Antibody, On-Target (AES-0622-ZP693) (CAT#: AES-0622-ZP693)
Anti-BCMA Antibody, Non-Fucosylated (BioBet-1780ZP) (CAT#: BioBet-1780ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.